These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 28474297)

  • 21. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
    Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
    J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
    Rimel BJ; Dockery L; Randall LM; Moore K
    Future Oncol; 2020 Nov; 16(33):2701-2711. PubMed ID: 32880196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
    Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
    Musacchio L; Salutari V; Pignata S; Braicu E; Cibula D; Colombo N; Frenel JS; Zagouri F; Carbone V; Ghizzoni V; Giolitto S; Giudice E; Perri MT; Ricci C; Scambia G; Lorusso D
    Int J Gynecol Cancer; 2021 Oct; 31(10):1369-1373. PubMed ID: 34607820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
    Matulonis UA; Walder L; Nøttrup TJ; Bessette P; Mahner S; Gil-Martin M; Kalbacher E; Ledermann JA; Wenham RM; Woie K; Lau S; Marmé F; Casado Herraez A; Hardy-Bessard AC; Banerjee S; Lindahl G; Benigno B; Buscema J; Travers K; Guy H; Mirza MR
    J Clin Oncol; 2019 Dec; 37(34):3183-3191. PubMed ID: 31518175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
    Musacchio L; Palluzzi E; Di Napoli M; Lauria R; Ferrandina G; Angioli R; Bergamini A; Corrado G; Perniola G; Cassani C; Savarese A; Gori S; Greco F; De Angelis C; Zafarana E; Giannarelli D; Cinieri S; Mosconi AM; Raspagliesi F; Pignata S; Scambia G; Lorusso D
    Gynecol Oncol; 2024 May; 184():24-30. PubMed ID: 38277918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Niraparib for the treatment of ovarian cancer.
    Kanjanapan Y; Lheureux S; Oza AM
    Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Niraparib Slows Ovarian Cancer Progression.
    Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.
    Gallagher JR; Heap KJ; Carroll S; Travers K; Harrow B; Westin SN
    Future Oncol; 2019 Dec; 15(36):4197-4206. PubMed ID: 31707856
    [No Abstract]   [Full Text] [Related]  

  • 32. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
    Wu XH; Zhu JQ; Yin RT; Yang JX; Liu JH; Wang J; Wu LY; Liu ZL; Gao YN; Wang DB; Lou G; Yang HY; Zhou Q; Kong BH; Huang Y; Chen LP; Li GL; An RF; Wang K; Zhang Y; Yan XJ; Lu X; Lu WG; Hao M; Wang L; Cui H; Chen QH; Abulizi G; Huang XH; Tian XF; Wen H; Zhang C; Hou JM; Mirza MR
    Ann Oncol; 2021 Apr; 32(4):512-521. PubMed ID: 33453391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and dose modification for patients receiving niraparib.
    Berek JS; Matulonis UA; Peen U; Ghatage P; Mahner S; Redondo A; Lesoin A; Colombo N; Vergote I; Rosengarten O; Ledermann J; Pineda M; Ellard S; Sehouli J; Gonzalez-Martin A; Berton-Rigaud D; Madry R; Reinthaller A; Hazard S; Guo W; Mirza MR
    Ann Oncol; 2018 Aug; 29(8):1784-1792. PubMed ID: 29767688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
    Pothuri B; Han S; Chase DM; Heitz F; Burger RA; Gaba L; Van Le L; Guerra E; Bender D; Korach J; Cloven N; Churruca C; Follana P; DiSilvestro P; Baurain JF; Jardon K; Pisano C; Peen U; Mäenpää J; Gupta D; Bacqué E; Li Y; Compton N; Antonova J; Monk BJ; González-Martín A
    Gynecol Oncol; 2024 May; 184():168-177. PubMed ID: 38325276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC; Coleman RL; Westin SN
    Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
    Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human mass balance study and metabolite profiling of
    van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
    Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Niraparib - A promising drug with hematological toxicity.
    Patibandla NS; Monga DK
    J Oncol Pharm Pract; 2019 Oct; 25(7):1749-1753. PubMed ID: 30293481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
    Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE
    Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.